San Diego Multidisciplinary Thoracic Oncology Symposium: Patient-centered approach to improve outcomes 2022 San Diego United States
This CME-accredited activity “San Diego Multidisciplinary Thoracic Oncology Symposium: Patient-centered approach to improve outcomes” features leading experts in thoracic malignancies who will provide a comprehensive overview of current and emerging strategies for management of lung cancer (NSCLC, SCLC), mesothelioma, and thymic malignancies. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with thoracic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in molecular testing and targeted-therapies for thoracic oncology. Expert faculty will aim to place the role of different therapeutic agents in clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.
The symposium will augment healthcare providers’ foundation of knowledge and clinical competence in several areas, including:
- Neoadjuvant and adjuvant treatment of non-small cell lung cancer (NSCLC) including specific roles of immune-checkpoint inhibitors, targeted therapy, and chemotherapy.
- Role of different platforms, including next generation sequencing and PD-L1 assessment to identify treatment options in NSCLC.
- Appropriate use of systemic therapy in small cell lung cancer (SCLC)
- Novel approaches to the treatment of mesothelioma and thymic malignancies
- Trends, challenges, controversies, and limitations of precision oncology approaches and targeted therapies in management of thoracic malignancies.
TARGET AUDIENCE
- Medical Oncologists
- Surgeons
- Radiation Oncologists,
- Pathologists Oncology Fellows
- Oncology Nurses
- Nurse Practitioners
- Physician Assistants
- Pharmacists
LEARNING OBJECTIVES
Upon successful completion of this educational activity, participants will be able to:
- Review frequent molecular abnormalities in NSCLC, and appropriate testing and treatment
- Outline efficacy and toxicities of immune checkpoint inhibitors, targeted therapy, and other chemotherapy agents in management of management of NSCLC
- Identify the role of neoadjuvant and adjuvant systemic therapy options in curative-intent treatment of NSCLC, including the role of chemotherapy, immune checkpoint inhibitors and targeted therapy.
- Incorporate appropriate sequencing of treatment options in patients with mesothelioma and thymic malignancies.
- Integrate emerging evidence in precision oncology into testing and treatment paradigms for treatment of thoracic malignancies.
Multidisciplinary Thoracic Oncology Symposium: Patient-centered approach to improve outcomes
We are not accepting Abstracts.
